Stock Screener App

Frei -

Installieren

4.98

0.40% -0.02

after-market

Handel nachbörslich: 4.84 -0.14 -2.81%

Moleculin Biotech Inc (MBRX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten

Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus

HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq

Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria

Moleculin Biotech Enters Inducement Offer Agreements - TipRanks

Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com UK

Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times

Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative

Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan

Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io

Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN

Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus

Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks

Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria

Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView

Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com Canada

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm

Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire

Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com South Africa

Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks

Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus

Moleculin enters research agreement for brain cancer treatment - Investing.com

Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times

Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative

Moleculin announces new Annamycin collaboration in brain tumors - marketscreener.com

Moleculin (Nasdaq: MBRX) joins CIC biomaGUNE to study Annamycin in GBM models - Stock Titan

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Moleculin Biotech (MBRX) Price Target Increased by 2,399.99% to 170.00 - Nasdaq

Net debt of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView

After tax other income/expense of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView

Basic earnings per share (basic EPS) of Moleculin Biotech, Inc. – LS:A41SET - TradingView

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.

Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ

Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MOL0 | US60855D4088 - marketscreener.com

Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | MOL0 | US60855D4088 - marketscreener.com

Moleculin Biotech, Inc.: Dividend historical data and projections - marketscreener.com

Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | MOL0 | US60855D4088 - marketscreener.com

How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser

Moleculin Biotech Inc (FRA:MOL0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Moleculin Biotech Inc (FRA:MOL0) Stock Earnings Transcripts - GuruFocus

Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser

Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Price to cash flow ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Why analysts maintain buy rating on Moleculin Biotech Inc. (MOL) stockGDP Growth & Reliable Momentum Entry Alerts - Newser

Number of employees of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView

Moleculin Biotech, Inc. Financial Statements – FWB:MOL0 - TradingView

Net debt of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Non-controlling/minority interest of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Diluted net income available to common stockholders of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Operating income of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Gross profit of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Moleculin Biotech, Inc. Statistics – BER:MOL0 - TradingView

Non-operating income (total) of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Taxes of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Diluted earnings per share (diluted EPS) of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Preferred dividends of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Moleculin Biotech, Inc. Cash Flow – BER:MOL0 - TradingView

Moleculin Biotech, Inc. Balance Sheet – BER:MOL0 - TradingView

Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | | US60855D4088 - marketscreener.com

Moleculin Biotech, Inc. Financial Statements – BER:MOL0 - TradingView

Moleculin Biotech: Target Price Consensus and Analysts Recommendations | MOL | US60855D3098 - marketscreener.com

Moleculin Biotech: Dividend historical data and projections - marketscreener.com

Moleculin Biotech: Revenue and Earnings Analysts Forecasts Revisions | MOL | US60855D3098 - marketscreener.com

Number of employees of Moleculin Biotech, Inc. – BER:MOL0 - TradingView

Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | | US60855D4088 - marketscreener.com

Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | | US60855D4088 - marketscreener.com

RPRX

$38.39

1.08%

INCY

$95.41

0.72%

GMAB

$31.31

3.07%

BNTX

$94.81

1.24%

ONC

$319.06

0.55%

INSM

$197.01

0.91%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters